Navigation Links
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Date:8/22/2008

9,395 Women Enrolled in Trial Sponsored by Medical Research Council

LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections. The trial is sponsored by the United Kingdom's Medical Research Council (MRC) and conducted by the Microbicides Development Programme (MDP), an international partnership of researchers established to develop microbicides for the prevention of HIV transmission. This trial enrolled 9,395 women at clinics in South Africa, Tanzania, Uganda, and Zambia. Results from this trial are expected to be available by the end of 2009.

This is the second large trial testing the safety and effectiveness of the 0.5% dose of PRO 2000 and the largest trial of any microbicide to date. In July 2007, enrollment of 3,100 women was completed in Protocol HPTN 035 sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Results from the HPTN 035 trial are expected to be available by early 2009.

"The completion of enrollment in this trial marks a significant milestone for Indevus, our shareholders and for women who may benefit from a product that provides a female-controlled option for HIV and STD prevention," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "We have now completed enrollment in two pivotal trials with over 12,000 women participating. If the trials are successful, we expect to be in a position to file marketing applications with regulatory authorities, in
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
6. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  TeamHealth Medical Call Center (THMCC), a ... advice lines, announces its newly formed Clinical Advisory ... administrative leaders, provides clinical expertise to advance THMCC,s ... for hospital clients, physician clients and patients. ... it,s imperative to continuously advance our services and ...
(Date:5/23/2013)... 23, 2013 More than half of women ... from chemotherapy and still have excellent outcomes. To educate ... of the largest sources of online consumer information about ... Facebook page provide recently diagnosed women with information sources, ... chemotherapy. "We anticipate these innovative social media ...
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... 24, 2013 Residents of San Diego ... camp classes. Fitness expert, and Certified Russian Kettlebell Instructor, ... X Bootcamps in San Diego, California. The classes take ... class times offered. Initial sign-ups are available online ... been teaching Kettlebell for years. The bootcamps being ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
(Date:5/24/2013)... schizophrenics? Finding the answer for this is at the centre ... from the Bergen fMRI Group at the University of Bergen ... voices. The way they do this is by studying people ... a mental illness. For a five-year period, the group is ... recent report published in Frontiers in Human Neuroscience ...
(Date:5/24/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Type ... with signs of serious complications seen just a few ... on the latest results, it seems like type 2 ... Chiang, senior vice president of medical affairs and community ... faster, and it appears to be at a more ...
Breaking Medicine News(10 mins):Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Help at hand for schizophrenics 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 3
... New Executive LeadershipKOBE, Japan, March 5 Sysmex ... medical diagnostics instrument manufacturer and laboratory information systems ... Corporate and its subsidiaries in the Americas, Europe ... Obe will return to Sysmex Corporate after a ...
... more than 3,000 women in the U.S. and southern ... a vaginal microbicide gel for preventing HIV infection in ... Retroviruses and Opportunistic Infections (CROI), one 0.5 % dose ... to cells in the genital tract, was 30% effective. ...
... printing superstore was honored for ecommerce expertise when President Michael Del ... version of the highly respected Entrepreneur magazine. , ... ... Del Chiaro for the interview based on his proven success in ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... Inc. (RPI), a wholly owned subsidiary of Ranbaxy ... received approval from the U.S. Food and Drug ... Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg ... was submitted by Ranbaxy, from its Ohm Laboratories ...
... a penile extender every day for six months were able ... to 32% and their erectile function by up to 36%, ... issue of BJU International . , Researchers from San ... now suggesting that this treatment could provide a viable alternative ...
Cached Medicine News:Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2
... Our slimmest full-featured bronchofiberscope yet. The BF-3C40's ... by 0.2mm from the previous model. It ... Olympus models, thanks to the use of ... enlarge the image size by 70 percent. ...
... designed specifically to enable direct inspection of ... for pediatric applications as well. Its insertion ... 2.8mm across. As a result, insertion into ... greater ease. And since this sophisticated scope ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. , Lung Lavage. ...
... double lumen tube made of silicone rubber with ... to the characteristics of silicone rubber, Silbronco is ... insertion. Furthermore, the tube will not soften like ... term surgery., ,Silbronco is also especially useful ...
Medicine Products: